Novel Aryltriazole Acyclic C-Azanucleosides as Anticancer Candidates - Archive ouverte HAL Access content directly
Journal Articles Organic & Biomolecular Chemistry Year : 2020

Novel Aryltriazole Acyclic C-Azanucleosides as Anticancer Candidates


Nucleoside analogues represent an important class of drug candidates. With the aim of searching for novel bioactive nucleosides, we developed an efficient synthetic way to construct a series of aryl 1,2,3-triazole acyclic C-azanucleosides via Huisgen 1,3-dipolar cycloaddition. The aryl 1,2,3-triazole motifs within these azanucleosides showed coplanar features, suggesting they could act as surrogates for large planar aromatic systems or nucleobases. Moreover, several aryltriazole acyclic C-azanucleosides bearing long alkyl chains exhibited potent antiproliferative activity against various cancer cell lines via induction of apoptosis. Most interestingly, the lead compound significantly down-regulated the key proteins involved in the heat shock response pathway, representing the first anticancer acyclic azanucleoside with such a mode of action. These novel aryl 1,2,3-triazole cyclic C-azanucleosides therefore serve as promising paradigms for further exploring anticancer drug candidates.
Fichier principal
Vignette du fichier
Revised Manuscript.pdf (733.43 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03041312 , version 1 (04-12-2020)



Yanhua Zhang, Yun Lin, Qianqian Hou, Xi Liu, Sabrina Pricl, et al.. Novel Aryltriazole Acyclic C-Azanucleosides as Anticancer Candidates. Organic & Biomolecular Chemistry, 2020, ⟨10.1039/d0ob02164d⟩. ⟨hal-03041312⟩
46 View
148 Download



Gmail Mastodon Facebook X LinkedIn More